Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byGlaxoSmithKline
Price$325M
Date5/2013

General Information

Offices

HQ
Elisabethenstrasse 3
Basel, CH 4051, CHE

People

Board of Directors

Funding

TOTAL $20.5M
FUNDING TOTAL $20.5M
Series B, 9/2010
Versant Ventures
Boehringer Ingelheim Venture Fund
$20.5M

Tags

Okairos

Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy.

The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.

Recent Milestones

Videos

Screenshots

Okairos screenshot
Above: Okairos Screenshot -- #1
Uploaded: 9/15/10

Sources

  1. GlaxoSmithKline Acquires Okairos for $325 Million (fool.com) [edit]
  2. Italy's Okairos raises $20.5M for vaccine work (fiercebiotech.com) [edit]
Edit This Page
Last Edited 10/14/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy